Trident Texofab approved its financial results for FY26 and scheduled its 18th annual general meeting during a board session on September 7, 2026.

The company confirmed that the AGM will take place on September 30, 2026, at 4:00 pm via video conferencing or other audio-visual means. The register of members and share transfer books will remain closed from September 24 to September 30, 2026, inclusive. The cut-off date for remote e-voting is set for September 23, 2026.

Key Board Resolutions

The board recommended the reappointment of Mr. Manish Dhirajlal Halwawala, who retires by rotation. His appointment is subject to shareholder approval at the upcoming AGM. The board also appointed CS Mebul Amareliya as the scrutinizer for the e-voting process.

Cost Auditor Appointment

On the recommendation of the Audit Committee, the board appointed M/s. PAAA & Associates as the cost auditor for FY27. The firm holds registration number 006283 and will conduct the audit of cost records in accordance with Section 148 of the Companies Act, 2013.

The appointment was disclosed pursuant to Regulation 30 of SEBI Listing Regulations. The firm’s profile indicates expertise in cost management services, internal audit, project finance, and corporate compliances under the Companies Act, 2013.

Hardik Desai Family Trust has increased its stake in Trident Texofab by acquiring 8,643 equity shares in the open market on August 24, 2026. The transaction brings the trust’s total holding to 10,42,334 shares, representing a 6.95% stake in the company.

The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing, dated August 26, 2026, confirms that the trust belongs to the promoter group. Hardik Jigishkumar Desai signed the disclosure as trustee.

What the Numbers Show

The trust’s stake rose from 6.89% (10,33,691 shares) before the transaction to 6.95% after the purchase. This represents a marginal increase of 0.06 percentage points in voting rights. No shares were encumbered or pledged in this specific transaction.

Trident Texofab’s total equity share capital remains unchanged at ₹14,99,57,640, comprising 1,49,95,764 equity shares of ₹10 each. The diluted share capital also remains at this level, indicating no outstanding convertible securities or warrants affecting the denominator for this calculation.